" 5q- syndrome" . "2015-01-22+01:00"^^ . . "2012-04-01+02:00"^^ . "1"^^ . . . "1"^^ . . . . . "2015-12-31+01:00"^^ . . . "myelodysplastic syndrome" . . "0"^^ . . . " megakaryocytic dif" . "We want to contribute to further understanding of the 5q- syndrome pathogenesis mechanism by the study of the important transcription factors, EKLF (erythroid Kr\u00FCppel like factor, also called KLF1), Fli1 (Friend leukemia virus integration 1) and GATA1, which take part together with other factors on the differentiation of common MEP progenitor cell into erythroid or megakaryocytic line. The expression of these and other important genes in this mechanism will be analysed in separated bone marrow and blood cells of patients MDS with 5q- syndrom in comparison with low-risk MDS with normal chromosome 5 and with healthy controls by TaqMan real-time PCR. Our second aim is to contribute to the understanding of the mechanism of the effective agent lenalidomide in patients with 5q- syndrome in comparison with low-risk MDS with normal chromosome 5. Mutations of EKLF, which can significantly affect lenalidomide treatment, will be also detected."@en . "myelodysplastic syndrome; 5q- syndrome; erythroid , megakaryocytic dif; gene expression; lenalidomide"@en . "Chceme p\u0159isp\u011Bt k objasn\u011Bn\u00ED mechanismu patogeneze 5q \u2013 syndromu studiem d\u016Fle\u017Eit\u00FDch transkrip\u010Dn\u00EDch faktor\u016F, EKLF (\u201Cerythroid Kr\u00FCppel-like factor\u201C, ozna\u010Dovan\u00FD tak\u00E9 KLF1), Fli1 (\u201CFriend leukemia integration 1\u201C) a GATA1, kter\u00E9 se krom\u011B \u0159ady dal\u0161\u00EDch faktor\u016F pod\u00EDlej\u00ED na diferenciaci spole\u010Dn\u00E9 progenitorov\u00E9 bu\u0148ky MEP (\u201Cmegakaryocyte-erythroid progenitor\u201C) do erytroidn\u00ED nebo megakaryocyt\u00E1rn\u00ED \u0159ady. Expresi uveden\u00FDch a dal\u0161\u00EDch gen\u016F, potenci\u00E1ln\u011B d\u016Fle\u017Eit\u00FDch v tomto mechanismu, chceme zkoumat metodou kvantitativn\u00ED TaqMan RT-PCR v re\u00E1ln\u00E9m \u010Dase na pacientech MDS s 5q- syndromem ve srovn\u00E1n\u00ED s MDS o n\u00EDzk\u00E9m riziku a s norm\u00E1ln\u00EDm chromozomem 5 a se zdrav\u00FDmi kontrolami na separovan\u00FDch bu\u0148k\u00E1ch kostn\u00ED d\u0159en\u011B a perifern\u00ED krve. Na\u0161\u00EDm druh\u00FDm z\u00E1m\u011Brem je p\u0159isp\u011Bt k objasn\u011Bn\u00ED mechanismu \u00FA\u010Dinku \u00FA\u010Dinn\u00E9 imunomodula\u010Dn\u00ED l\u00E1tky lenalidomidu u pacient\u016F s 5q- syndromem ve srovn\u00E1n\u00ED s MDS o n\u00EDzk\u00E9m riziku a s norm\u00E1ln\u00EDm chromozomem 5. Budou analyzov\u00E1ny mutace EKLF, kter\u00E9 mohou v\u00FDznamn\u011B ovlivnit odpov\u011B\u010F na lenalidomid." . "NT13836" . . . "The study of the myelodysplastic syndrome pathogenesis in patients with isolated del(5q) abnormality and the analysis of the effect of lenalidomide"@en . "2014-03-21+01:00"^^ . . . " gene expression" . . "6"^^ . " erythroid " . "http://www.isvav.cz/projectDetail.do?rowId=NT13836"^^ . "6"^^ . "Studium patogeneze myelodysplastick\u00E9ho syndromu u pacient\u016F s izolovanou aberac\u00ED del(5q) a anal\u00FDza \u00FA\u010Dinku lenalidomidu" .